1. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy Nature reviews. Drug Discov 8:235–253
2. Fatemeh D, Barkhordari F, Alebouyeh M, Adeli A, Mahboudi F (2011) Combined TGE-SGE expression of novel PAI-1-resistant t-PA in CHO DG44 cells using orbitally shaking disposable bioreactors. J Microbiol Biotechnol 21:1299–1305
3. Ferrer MN, Domingo EJ, Corchero JL, Vazquez E, Villaverde A (2009) Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 8:17
4. Frank BH, Chance RE (1985) The preparation and characterization of human insulin of recombinant DNA origin. In: Joyeaux A, Leygue G, Morre M, Roncucci R, Schmelck PH (eds) Therapeutic agents produced by genetic engineering “Quo Vadis”. Toulouse-Labege, Symposium Sanofi Group, Paris MEDSI, pp 137–46
5. Galloway JA (1988) Chemistry and clinical use of insulin. In: Galloway JA, Potwin JH, Shuman CR (eds) Diabetes Mellitus, 9th edn. Lilly, Indianapolis, pp 106–137